Are peptides legal to compound in 2026? The FDA record, dated

What the categories mean

Section 503A of the Food, Drug and Cosmetic Act lets a pharmacy compound a medicine from a bulk substance only if that substance is the subject of an approved drug, has a USP or NF monograph, or appears on a list the FDA maintains. Substances nominated for that list are sorted, under an interim policy, into Category 1 (no significant safety risk identified; the FDA exercises enforcement discretion while rulemaking runs), Category 2 (a significant safety risk identified; compounding is not permitted and the listing supports enforcement action) and Category 3 (not enough information to evaluate). Removal from Category 2 is not permission: it withdraws the safety finding and nothing else. A substance that has come off Category 2 but has not been placed in Category 1 or on the list sits in a grey area where nothing is prohibited and nothing is authorised. Only a final rule after notice-and-comment rulemaking settles it.

The timeline

1. September 2023

   FDA places a batch of peptides in Category 2

   Reviewing substances nominated for pharmacy compounding under section 503A, the FDA placed nineteen peptide bulk substances in Category 2, the tier reserved for substances where it had identified a significant safety risk. The effect was immediate and practical: a compounding pharmacy could no longer lawfully use them, and the listing supported enforcement action against those that did. Agency reviewers cited three recurring problems — immunogenicity in molecules deliberately engineered to persist longer than the natural peptide, manufacturing impurities including bacterial contamination and heavy metals, and human data that was thin or absent for the uses being sold.

   Sources: FDA evaluation of bulk drug substances nominated for use in compounding under section 503A (Category 2 listings) · ProPublica, "An FDA Reversal on Peptides Could Open the Market to Unsafe Drugs" (Anjeanette Damon, 3 April 2026)

2. 27 February 2026

   The Health Secretary promises access on a podcast

   Robert F. Kennedy Jr told Joe Rogan that he was "a big fan of peptides", that he had used them himself, and that the 2023 restrictions had backfired: "We created the gray market." He said an announcement restoring access to roughly fourteen peptides was weeks away. That interview, rather than any new trial result, is what moved the regulatory position.

   Sources: NPR, on the Health Secretary’s peptide announcement and the compounding market (31 March 2026)

3. 15 April 2026

   Twelve peptides come off Category 2 — which is not the same as permission

   The FDA announced the removal of twelve peptide bulk substances from Category 2, effective seven days later: BPC-157, TB-500, MOTS-c, KPV, semax, epitalon, DSIP, injectable GHK-Cu, LL-37, dihexa acetate, PEG-MGF and melanotan II. Removal withdraws the significant-safety-risk finding that supported enforcement, and does nothing else. It does not place a substance on the 503A bulks list and does not move it into Category 1, so these compounds entered a grey area in which nothing is prohibited and nothing is authorised. In the same notice GHK-Cu for non-injectable routes was taken out of Category 1, because its nominations had been withdrawn too.

   Sources: Orrick, "FDA Announces Removal of 12 Peptides from Category 2 and Schedules PCAC Meetings" (April 2026) · BioPharma Dive, "FDA moves toward easing restrictions on certain peptides"

4. 14 May 2026

   Non-injectable GHK-Cu goes back into Category 1

   On 5 May one of the nominators told the FDA it had meant to withdraw only its nomination for injected GHK-Cu. The FDA’s updated list of 14 May put GHK-Cu for non-injectable routes back into Category 1, the tier under evaluation with no significant safety risk identified. Injected GHK-Cu stayed out of both categories. The agency said it would consult its compounding advisory committee on GHK-Cu before the end of February 2027.

   Sources: FDA, Bulk drug substances nominated for use in compounding under section 503A: category lists, updated 14 May 2026 (GHK-Cu returned to Category 1 for non-injectable routes)

5. 23 July 2026

   The advisory committee votes yes on six, against the agency’s own scientists

   Over two days the Pharmacy Compounding Advisory Committee considered seven peptides. It voted to recommend six for the 503A bulks list: BPC-157 for ulcerative colitis, KPV for wound healing and inflammatory conditions, and TB-500 for wound healing each passed eight to six with one abstention; MOTS-c for obesity and osteoporosis passed seven to five with two abstentions; semax passed eight to five and epitalon seven to five. DSIP was the single rejection, voted down six to seven. Every vote was close, and every one overruled FDA career scientists, who had recommended against all seven on the grounds that they lacked the evidence to assess safety or effectiveness — and that without universally accepted chemical definitions for these substances, basic identity, quality and comparability between products are unclear.

   Sources: FDA, Pharmacy Compounding Advisory Committee meeting, 23–24 July 2026 (docket FDA-2025-N-6895) · Pharmaceutical Executive, "FDA Panel Votes to Loosen Restrictions for Four Peptides" (24 July 2026) · AJMC, "FDA Panel Backs 6 Peptides for Compounding" · The Hill, "FDA panel votes to add peptides to permitted compounding list despite opposition from agency scientists"

6. 15 September 2026

   Where it actually stands today

   Nothing has been approved, and nothing on this list has become an approved drug. A committee recommendation is advisory: the FDA still has to act, and Category 1 placement runs through notice-and-comment rulemaking that commentators expect to take eight to twelve months and run into 2027. A pharmacy reading the July votes as authorisation to start compounding would be getting ahead of the record. Separately, four peptides never left Category 2 and are the subject of a court challenge, with a final rule expected no later than March 2027. A second advisory meeting on the remaining substances is due before the end of February 2027.

   Sources: Buchanan Ingersoll & Rooney, "FDA Voted Yes on Six Peptides. Now What? The Regulatory Road Ahead" · Frier Levitt, on the Administrative Procedure Act challenge to four Category 2 peptide placements

Every affected peptide on this site

Sorted by where each compound stands. The badge is repeated on the monograph itself, in the regulatory section, so the two can never disagree.

The four that never left Category 2

An Administrative Procedure Act suit brought by Evexias and Farmakeio challenged the transparency of the Category 2 placements for four peptides: CJC-1295, ipamorelin acetate, AOD-9604 and thymosin alpha-1. The FDA agreed to accelerate its review of the four. The case has been administratively closed pending publication of a final rule, which the agency has represented is expected no later than 14 March 2027. Until that rule publishes, all four remain in Category 2 and are not eligible for lawful pharmacy compounding in the United States.

What the FDA’s own scientists said

The July 2026 votes are usually reported as the FDA loosening its position. It is more accurate to say the advisory committee overruled the agency’s reviewers. Career scientists recommended against all seven substances on two grounds: that the human evidence was insufficient to assess either safety or effectiveness, and that without a universally accepted chemical definition of what, say, "BPC-157" is, the identity, quality and comparability of one product against another cannot be established. The second point is the one that matters most for anyone holding a vial: it means that even after a substance is listed, "BPC-157" from two pharmacies may not be the same molecule in the same purity. Earlier agency reviews, reported by ProPublica, documented immunogenicity risk in peptides engineered to persist longer than the natural molecule, manufacturing impurities including bacterial contamination and heavy metals, and, for six of the nineteen substances listed in 2023, adverse events in human studies, including deaths, without causation established. Former Acting Commissioner Janet Woodcock called the reversal "a disruption of the societal pact we have had since 1962 that drugs will be studied to see if they work before they are marketed."

How to read a claim that a peptide is now legal

• "Removed from the banned list" means off Category 2. It does not mean on the bulks list, in Category 1, or approved.
• "FDA panel approved" means an advisory committee voted to recommend. The FDA has not acted on the recommendation as of 15 September 2026, and a recommendation binds nobody.
• "Compounded" means made by a pharmacy under a prescription. A research-use-only vial bought online is not compounded, and none of this record makes it lawful to sell for human use.
• "Approved" should mean an approved drug application. No compound on this page has one for the uses it is sold for; several have never been in a human efficacy trial.

Record last checked 15 September 2026 against the FDA advisory committee calendar, the agency’s section 503A pages, and the reporting and legal analyses linked above. If you can show us a primary source that changes any line on this page, tell us and we will re-date it.